Atossa Therapeutics Announces Sponsored Research Agreement With Weill Cornell Medicine To Study The Potential Of Inducing Estrogen Receptor Expression In Triple Negative Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
Atossa Therapeutics has announced a sponsored research agreement with Weill Cornell Medicine to study the potential of inducing estrogen receptor expression in triple negative breast cancer.
July 06, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atossa Therapeutics' new research agreement with Weill Cornell Medicine could potentially lead to advancements in breast cancer treatment, which may positively impact the company's stock.
The news of Atossa Therapeutics entering into a research agreement with Weill Cornell Medicine is directly related to the company and its operations. If the research yields positive results, it could lead to advancements in breast cancer treatment, which could increase the company's market value and positively impact its stock price.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100